As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...

Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408.Maximize Your Portfolio with Data ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals ... use the check-ins as a way to collect people’s health problems and convert them into lucrative billing codes.

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals ... management and establish a new standard of care,” Kewalramani said.

The 76ers on Sunday made official the conversion of Justin Edwards’ two-way contract to a standard deal, something rendered a formality given the undrafted rookie’s recent play. The Sixers ...

Anthony Slater: Steph Curry is cleared to play tonight vs Thunder. Sounds like Quinten Post could enter the starting lineup. Steve Kerr wouldn’t reveal, but joked he’s trying to “set a ...